key: cord-0978148-5a6ixiaf
authors: Palladino, Giuseppe; Chang, Cheng; Lee, Changkeun; Music, Nedzad; De Souza, Ivna; Nolasco, Jonathan; Amoah, Samuel; Suphaphiphat, Pirada; Otten, Gillis R.; Settembre, Ethan C.; Wen, Yingxia
title: Self-amplifying mRNA SARS-CoV-2 vaccines raise cross-reactive immune response to variants and prevent infection in animal models
date: 2022-03-23
journal: Mol Ther Methods Clin Dev
DOI: 10.1016/j.omtm.2022.03.013
sha: 2a1e16b1ea52eb6a87ef429edfe05f7a15fdbdbc
doc_id: 978148
cord_uid: 5a6ixiaf

The spike (S) protein of SARS-CoV-2 plays a crucial role in cell entry, and the nucleocapsid (N) protein is highly conserved among human coronavirus homologs. For potentially broad effectiveness against both original virus and emerging variants, we developed alphavirus-based self-amplifying mRNA (sa-mRNA) SARS-CoV-2 vaccines: an sa-mRNA S encoding a full-length S protein stabilized in a prefusion conformation and an sa-mRNA S-N co-expressing S and N proteins for the original virus. We show that these sa-mRNA SARS-CoV-2 vaccines raised potent neutralizing antibody responses in mice against not only the original virus but also the alpha, beta, gamma, and delta variants. sa-mRNA S vaccines against the alpha and beta variants also raised robust cross-reactive neutralizing antibody responses against their homologous viruses and heterologous variants. sa-mRNA S and sa-mRNA S-N vaccines elicited Th1-dominant, antigen-specific CD4+ T cell responses to S and N proteins and robust and broad CD8+ T cell responses to S protein. Hamsters immunized with either vaccine were fully protected from lung infection and showed significant reduction of viral load in upper respiratory tract. Our findings demonstrate that sa-mRNA SARS-CoV-2 vaccines are potent in animal models with potential to be highly effective against SARS-CoV-2 infection in humans.

self-amplifying mRNA (sa-mRNA) SARS-CoV-2 vaccines: an sa-mRNA S encoding a full-23 length S protein stabilized in a prefusion conformation and an sa-mRNA S-N co-expressing S 24 and N proteins for the original virus. We show that these sa-mRNA SARS-CoV-2 vaccines 25 raised potent neutralizing antibody responses in mice against not only the original virus but also 26 the alpha, beta, gamma, and delta variants. sa-mRNA S vaccines against the alpha and beta 27 variants also raised robust cross-reactive neutralizing antibody responses against their 28 homologous viruses and heterologous variants. sa-mRNA S and sa-mRNA S-N vaccines elicited Immune response in mice 106 To evaluate the antibody immune response by sa-mRNA vaccines in a preclinical animal model, 107 female BALB/c mice were immunized at Day 1 with either sa-mRNA S or sa-mRNA S-N at a 108 dose of 1 µg RNA ( Fig. 2A) . Half of the animals were boosted at Day 22 with the same vaccines 109 used for priming, and all animals were sacrificed at Day 43. Serum was tested for antibodies 110 neutralizing Vero E6 cell infection by homologous original virus and for antibodies inhibiting S 111 protein binding to the ACE2 receptor. Both assays showed that immunization with 1 dose of 112 either sa-mRNA S or sa-mRNA S-N generated neutralizing antibody titers. Microneutralization 113 (MN) geometric mean titer (GMT) was 211 for sa-mRNA S and 98 for sa-mRNA S-N (Fig. 2B) . 114 The GMT for ACE2-binding inhibition was 1,004 for sa-mRNA S and 941 for sa-mRNA S-N 115 (Fig. 2C ). The boost dose increased MN GMT ≥10-fold to 2,774 for sa-mRNA S and 1,280 for 116 sa-mRNA S-N. The GMTs for ACE2-binding inhibition were also increased ≥10-fold to 12,592 117 for sa-mRNA S and 10,791 for sa-mRNA S-N. With the same assay protocols, 8 human COVID-118 19 convalescent plasma samples were shown to have GMTs of 199 for MN (Fig. 2B ) and 1,715 119 for ACE2-binding inhibition, comparable to the titers raised with a single dose but ~10-fold 120 lower than those raised with two doses of sa-mRNA S or sa-mRNA S-N. 121 122 To confirm the neutralizing antibody response, additional studies were performed with both 8 During our study, new SARS-CoV-2 variants of concern, the alpha, beta, gamma, and delta 148 variants, emerged and started to spread, with the potential to be more infectious and virulent than 149 the earlier pandemic viruses. [19] [20] [21] [22] To evaluate the cross-reactivity of antibodies generated with sa- In addition to antibody response, T-cell responses in BALB/c and C57BL/6J mice raised with sa-170 mRNA S and sa-mRNA S-N were evaluated. Spleens from BALB/c mice were collected on Day 171 43 and tested for S-specific and N-specific CD4+ and CD8+ T cells. Splenocyte suspensions 172 were cultured in the presence or absence of synthetic peptide pools representing full-length S or 173 N protein, and cultures were analyzed for cell surface markers and intracellular cytokines. 174 Immunization with sa-mRNA S or sa-mRNA S-N resulted in both CD4+ ( Similar frequencies of S1-and S2-reactive CD4+ T cells were found. For CD8+ T cells, S1-185 reactive T cells dominated over S2-reactive T cells, with a broad cytokine phenotype, including 186 triple, double, and single cytokine-producing CD8+ T cells (Fig. 5B, D) . The T-cell responses in C57BL/6J mice raised by sa-mRNA S and sa-mRNA S-N were 189 evaluated with the same approaches and the tests showed similar robust CD4+ and CD8+ T cell To evaluate protection from viral infection, average virus recovery was compared between 209 hamsters immunized with sa-mRNA S, sa-mRNA S-N, and Adj-Pro S and control hamsters 210 immunized with phosphate-buffered saline (PBS). In the lung, the viral titer from control 211 hamsters was 5,011,872 50% tissue culture infectious dose per gram (TCID50/g) and from 212 vaccine-immunized hamsters was <20 TCID50/g, under the limit of quantitation of the assay and 213 demonstrating full lower respiratory tract protection with all 3 vaccines (Fig. 6C ). In the upper 214 respiratory tract (Fig. 6D ), virus recovery from nasal turbinates was 120,226,443 TCID50/g in 215 control hamsters. In immunized hamsters, viral titers were reduced ~10 4 -fold, 1,995 and 9,120 216 TCID50/g for the 3.0 and 0.3 µg doses of sa-mRNA S, respectively, and 14,454 and 21,878 217 TCID50/g for the 3.0 and 0.3 µg doses of sa-mRNA S-N, respectively. The viral recovery from 218 Adj-Pro S-immunized hamsters was reduced ~10 2 -fold, 1,000,000 TCID50/g, although the 219 neutralizing antibody titers raised by Adj-Pro S were comparable to 0.3 µg of sa-mRNA S and 220 sa-mRNA S-N (Fig. 5B ). Immunization also reduced the loss of body weight for hamsters caused 221 by SARS-CoV-2 virus infection (Fig. S4 ). In this study, a single dose at 1 µg or two doses at 0.01 µg each of either sa-mRNA SARS-CoV-237 original virus that were comparable to those from convalescent patient plasma. Neutralizing 239 antibody responses were robust against not only homologous original virus but also the alpha, 240 beta, gamma, and delta variants. In particular, we observed reduced but robust neutralizing 241 antibody response, especially by sa-mRNA S-N vaccine, against the delta virus, which differs 242 antigenically from the original strain and has been resistant to neutralizing antibodies generated 243 from convalescent plasma. 19, 21, 22 244 245 In addition to neutralizing antibodies, sa-mRNA SARS-CoV-2 vaccines also elicited antigen- 

Genomic characterisation and epidemiology of 2019 novel 514 coronavirus: implications for virus origins and receptor binding

A new coronavirus associated with human 517 respiratory disease in China

The spike protein of 519

Viral targets for vaccines against COVID-19

*P<0.05. **P<0.01. ***P<0.001. ****P<0.0001. ns, not significant (P≥0.05)

Each dot represents 663 an individual serum sample, and the column represents the geometric mean for the group. The 664 dotted line in each panel represents the lower limit of quantitation for the assay. Total virus 665 recovery from lung (C) and nasal turbinates (D) expressed as TCID50/g of tissue. Each dot 666 represents an individual sample, and the line the geometric mean for the group. The dotted line in 667 each panel represents the lower limit of quantitation for the assay. Statistical analysis by two-668 way ANOVA with Tukey's multiple comparison test was performed using GraphPad Prism 669 9